Published in Br J Cancer on December 01, 2003
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol (2012) 1.57
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol (2012) 1.44
Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res (2006) 1.09
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer (2006) 0.89
NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. J Transl Med (2008) 0.85
Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy. Neurotox Res (2013) 0.85
Proposed medications for taxane-induced myalgia and arthralgia (Review). Oncol Lett (2012) 0.83
Melatonin, a promising role in taxane-related neuropathy. Clin Med Insights Oncol (2010) 0.79
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer (2006) 0.78
A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Support Care Cancer (2013) 0.75
Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. Pharmacogenomics J (2015) 0.75
Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know. Eplasty (2017) 0.75
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Assesment of quality-of-life outcomes. N Engl J Med (1996) 8.66
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol (2000) 1.95
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev (1993) 1.74
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol (1998) 1.46
A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess (2000) 1.32
Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol (1999) 1.22
Quality of life of women with ovarian cancer. Gynecol Oncol (1995) 1.19
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol (2001) 1.13
Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol (2001) 1.07
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol (1997) 1.07
Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer (2001) 1.02
Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf (2000) 0.99
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer (2001) 0.99
Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol (2002) 0.98
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs (1996) 0.97
Quality of life in women with ovarian cancer. West J Nurs Res (1997) 0.93
New options for the treatment of advanced ovarian cancer. Semin Oncol (1997) 0.87
Quality of life: gynaecological cancers. Ann Oncol (2001) 0.87
Quality of life in patients with ovarian cancer: current state of research. Support Care Cancer (1996) 0.87
Future directions for the management of ovarian cancer. Eur J Cancer (2001) 0.85
Intravenous chemotherapy for ovarian cancer - the state of the art? Int J Gynecol Cancer (2000) 0.84
Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis. Eur J Cancer (1990) 0.81
Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. Int J Gynecol Cancer (2003) 0.78
Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis. Int J Gynecol Cancer (1992) 0.78
ESMO recommendations for the application of haematopoietic growth factors (hGFs). Ann Oncol (2001) 0.77
[Patient compliance and the quality of life are well maintained in weekly paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women]. Gan To Kagaku Ryoho (2001) 0.76
Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol (2010) 1.35
Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol (2008) 1.33
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol (2008) 1.31
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol (2012) 1.22
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer (2001) 1.17
Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer (2003) 1.14
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol (2010) 1.12
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer (2000) 1.12
First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol (2013) 1.12
Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology (2001) 1.07
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer (2000) 0.98
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer (2007) 0.98
Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. Br J Cancer (2012) 0.87
Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast (2004) 0.87
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). Br J Cancer (1998) 0.86
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann Oncol (2013) 0.85
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer (2012) 0.84
Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Res Treat (2014) 0.83
Is primary chemotherapy useful for all patients with primary invasive breast cancer? Recent Results Cancer Res (1998) 0.78
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Br J Cancer (2008) 0.77
Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol (2001) 0.76
[Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer]. Therapie (2000) 0.75
First line protracted venous infusion fluorouracil with CisDDP or carboplatine in advanced colorectal cancer. Clin Ter (1997) 0.75
Meningeal carcinomatosis in HER2-overexpressing breast cancers. J Neurooncol (2009) 0.75
First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer. J Infus Chemother (1996) 0.75
Differential expression of Bax and Bcl-2 in the assessment of cellular dynamics in fine-needle samples of primary breast carcinomas. Cytometry (2000) 0.75
Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma. Gynecol Oncol (1997) 0.75